Exosome-based therapeutics represent a paradigm shift in regenerative medicine, offering a cell-free approach for treating chronic wounds.
Exosome-based therapies represent a paradigm shift in regenerative medicine, offering a cell-free approach for promoting wound healing.
Mesenchymal stem cell (MSC)-derived exosomes and other extracellular vesicles (EVs) represent a promising cell-free therapeutic platform with significant advantages over whole-cell therapies.
This article provides researchers, scientists, and drug development professionals with a systematic framework for preserving exosome integrity during storage and processing.
Mesenchymal stem cell-derived exosomes (MSC-Exos) hold immense therapeutic promise, but their clinical translation is critically limited by challenges in obtaining sufficient quantities.
The therapeutic potential of Mesenchymal Stem Cell (MSC)-derived exosomes in regenerative medicine, immunotherapy, and drug delivery is immense.
The transition to serum-free media (SFM) is a critical advancement for the scalable and reproducible production of clinical-grade exosomes.
Chronic wounds represent a significant clinical challenge, driving the need for innovative regenerative therapies.
This article provides a critical analysis of current strategies for dosing and administering mesenchymal stem cell-derived exosomes (MSC-Exos) in wound therapy.
Chronic wounds represent a significant clinical challenge due to their complex pathophysiology and failure to progress through normal healing stages.